Team:Hong Kong HKUST/hp/interview/yu

From 2013.igem.org

(Difference between revisions)
(Created page with "<html> <head> <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"> </script> <script type="text/javascript"> $(document).ready(function(){ $("ul.first ...")
 
(35 intermediate revisions not shown)
Line 69: Line 69:
{visibility:hidden;}
{visibility:hidden;}
#globalWrapper
#globalWrapper
-
{position: relative;font-size:127%;width:100%;margin:0;padding:0;padding-bottom:10px;background-color:#494042;height:9100px;}
+
{position: relative;font-size:127%;width:100%;margin:0;padding:0;padding-bottom:10px;background-color:#494042;height:1350px;}
#content
#content
-
{width: 995px;border:none;background-color:#ffffff;height:9000px;padding:0px;margin-top:0px;line-height: 1.5em;color: black;}
+
{width: 995px;border:none;background-color:#ffffff;height:1300px;padding:0px;margin-top:0px;line-height: 1.5em;color: black;}
#top-section
#top-section
{height:2px;border:none;background-color:#494042;}
{height:2px;border:none;background-color:#494042;}
Line 167: Line 167:
top:141px;
top:141px;
width:100%;
width:100%;
 +
z-index:1;
}
}
#back-top {
#back-top {
Line 172: Line 173:
top: 10%;
top: 10%;
right: 2%;
right: 2%;
 +
z-index:16;
}
}
#back-top a {
#back-top a {
Line 239: Line 241:
width: 83.33333%;
width: 83.33333%;
top:192px;
top:192px;
-
z-index:-2;
+
 
}
}
.column, .columns {
.column, .columns {
Line 298: Line 300:
#msk3{margin-left:35px;}
#msk3{margin-left:35px;}
#msk4{margin-left:70px;}
#msk4{margin-left:70px;}
 +
 +
#iGEM_Logo{
 +
width:100px;
 +
height:80px;
 +
position:absolute;
 +
right:10px;
 +
top:60px;
 +
z-index:+15;
 +
}
 +
#hkust_Logo{
 +
width:60px;
 +
height:80px;
 +
position:absolute;
 +
right:110px;
 +
top:60px;
 +
z-index:+15;
 +
}
 +
 +
</style>
</style>
<body>
<body>
-
<p id="back-top" style=""display:none;>
+
 
 +
 
 +
          <a href="https://2013.igem.org/Main_Page"><img id="iGEM_Logo" src="https://static.igem.org/mediawiki/2013/4/46/Igem_qgem_logo.png"></a>
 +
         
 +
 
 +
<a href="http://www.ust.hk/eng/index.htm"><img id="hkust_Logo" src="https://static.igem.org/mediawiki/2013/5/55/Hkust_logo.gif"></a>
 +
 
 +
 
 +
<p id="back-top" style="display:none;">
<a href="#top"><span><img src="http://515alive.com/theme/img/up-arrow.png" style="width:90%;"><br><br>BACK TO TOP</span></a>
<a href="#top"><span><img src="http://515alive.com/theme/img/up-arrow.png" style="width:90%;"><br><br>BACK TO TOP</span></a>
</p>
</p>
Line 325: Line 354:
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/abstract">Abstract</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/abstract">Abstract</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/modules">Modules Description</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/modules">Modules Description</a></li>
 +
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/data">Data Page</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/Parts">Parts</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/Parts">Parts</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/characterization">Characterization</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/characterization">Characterization</a></li>
-
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/modelling">Modeling</a></li>
 
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/results">Result</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/results">Result</a></li>
 +
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/future">Future Work</a></li>
</ul>
</ul>
</li>
</li>
Line 337: Line 367:
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/protocols">Protocols</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/protocols">Protocols</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/safety">Safety</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/safety">Safety</a></li>
-
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/future">Future Work</a></li>
+
 
</ul>
</ul>
</li>
</li>
Line 350: Line 380:
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp">Human Practice</a>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp">Human Practice</a>
<ul>
<ul>
-
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview">Interviews</a></li>
 
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/cp">Country Profile</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/cp">Country Profile</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/blog">Blog</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/blog">Blog</a></li>
-
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/article">Article</a></li>
+
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview">Interviews</a></li>
 +
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/article/genet">Article</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/video">Videos</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/video">Videos</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/presentation">Presentations</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/presentation">Presentations</a></li>
Line 361: Line 391:
</ul>
</ul>
-
</div>
 
</div>
</div>
       <div class="row">
       <div class="row">
-
<div class="two columns">
+
<div class="two columns"><br>
-
<ul class="side-nav">
+
<ul class="side-nav">
<li>
<li>
-
<h6>Prof. Albert Yu</h6>
+
<h6>Interview</h6>
</li>
</li>
<li class="divider"></li>
<li class="divider"></li>
<li>
<li>
 +
Prof. Albert Yu<ul><li>
<a href=#1>Introduction</a>
<a href=#1>Introduction</a>
</li>
</li>
Line 380: Line 410:
</li>
</li>
<li>
<li>
-
<a href=#4>Interview Video</a>
+
<a href=#5>Pictures</a>
 +
</li><li>
 +
<a href=#6>Download Links</a>
</li>
</li>
-
<li>
+
</ul>
-
<a href=#5>RPictures</a>
+
</li>
</li>
-
 
-
 
-
 
-
</ul>
 
-
 
-
<ul class="side-nav1">
 
<li>
<li>
-
<h6>Interview</h6>
+
<a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview/chan">Prof. Juliana Chan</a>
-
</li>
+
-
<li class="divider"></li>
+
-
<li>
+
-
Prof. Albert Yu
+
-
</li>
+
-
<li>
+
-
<a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview/chan">Prof.Juliana Chan</a>
+
</li>
</li>
Line 408: Line 426:
<div class="row" id="ugd-members">
<div class="row" id="ugd-members">
<div class="twelve columns">
<div class="twelve columns">
-
<h2 class="centered">Indonesia</h2>
+
<h2 class="centered">Prof. Albert Yu</h2>
</div>
</div>
</div>
</div>
Line 414: Line 432:
<div class="nine columns"><p id="1"></p>
<div class="nine columns"><p id="1"></p>
<h3>Overview</h3>
<h3>Overview</h3>
-
This article will present information compiled from different online sources such as universities’ websites, newspaper, articles, and organizations’ websites. The information was searched both in English and Bahasa Indonesia. Information in Bahasa Indonesia was translated into English by Indonesian teammates. The general trend that we have notice from research is that information about synthetic biology in Indonesia is very limited. This might be due to the fact that not many people in Indonesia know about this subject. Information of biotechnology, however, was more abundant. Many companies and universities are participating in biotechnology development. Most of the research related to biotechnology focus on agriculture. In the future, following this trend in biotechnology, synthetic biology may also be used to improve agriculture in Indonesia.
+
Professor Albert Yu is the chairman of the Hong Kong Biotechnology Organization (HKBIO), and also a professor of the Department of Neurobiology of Peking University, China. As an entrepreneur and a scientist, Prof. Yu gave us realistic insights to our project. Meeting Prof. Yu helped us to evaluate our project beyond the laboratory environment and to think about its possible future application as a biotechnology product. Towards the end of the interview, we also talked about the bioethics and biosafety issues regarding synthetic biology.  
<br>
<br>
</div>
</div>
Line 422: Line 440:
<div class="nine columns"><p id="2"></p>
<div class="nine columns"><p id="2"></p>
-
<h3>Participation in the iGEM Competition</h3>
+
<h3>Main Discussion</h3>
-
Out of 3100 universities in Indonesia, only three universities in Indonesia joined the iGEM competition. This reflects that very few people know about the iGEM competition and synthetic biology. The first Indonesian university that joined the iGEM competition is Bogor Agricultural University (BAU). This university joined the iGEM 2012 competition, but did not manage to get any awards. Two universities from Indonesia, Bandung Institute of Technology (ITB) and University of Indonesia (UI), have registered for the iGEM 2013 competition<br><br>
+
Prof. Yu mentioned that our project is a small step and that we have a long way to go to apply our project as a commercial biotechnology product. He told us that because we are trying to insert genes into a human body, we need to be very careful with concluding how our project could be realistically applied in the future. Inserting genes into a human body can create novel metabolism properties that could lead to side effects. Also, because the general public considers obesity less harmful, people might be reluctant to sign up for invasive treatment if they believe a less invasive means such as exercising can solve the problem. He also encouraged us to look into other plant genes that could be used to cure fatal diseases.<br><br>  
-
<center><img src="https://static.igem.org/mediawiki/igem.org/b/b2/Indonesia_igem_competition_1.png" style="width:90%;"></center><br>
+
We also discussed about issues on biosafety and bioethics. Prof. Yu said that we need to be responsible scientists and utilize research to improve human life. He also mentioned that to produce a bioproduct, it is very important to consider the ethical issues of the project from the very start.
 +
<br>
   
   
</div>
</div>
Line 431: Line 450:
<div class="nine columns"><p id="3"></p>
<div class="nine columns"><p id="3"></p>
-
<h3>Funding of Biotechnology</h3>
+
<h3>Conclusion</h3>
-
<center><img src="https://static.igem.org/mediawiki/igem.org/e/e3/Indonesia_funding_of_biotechnology_1.png"></center><br>
+
The interview with Professor Albert Yu helped us to realize the social environment our project would encounter, and the barriers that come with it. The interview also showed that more in-depth consideration of our project’s future application is necessary if we want to see it utilized as a safe bioproduct.<br>
-
In 2012, Indonesian Institute of Science (LIPI) received around US$ 14 million from the Indonesian government ("Dana 2012," 2013). This amount of money is only around 0.1% from national income. This year, in 2013, the government proposed that they would decrease the funding to LIPI by 9% from the total amount of 2012 funding (“Riset bioteknologi: Terkendala,” 2012). This is one of the reasons why biotechnology in Indonesia is far behind that the other Asian countries. In fact, the total funding per gross domestic product for Indonesia is around 0.07%. This value is smaller than those of Ethiopia (0.17% and Colombia (0.16%). Even with lack of government funding, some institutes and universities have the urge to develop biotechnology. There are already around 30 institutes and some universities in Indonesia that joined to develop biotechnology industry.<br><br>
+
-
<center><img src="https://static.igem.org/mediawiki/igem.org/e/ef/Indonesia_funding_of_biotechnology_2.png"></center><br>
+
</div>
</div>
</div>
</div>
-
<div class="row">
 
-
<div class="nine columns"><p id="4"></p>
 
-
<h3>Perception of Synthetic Biology</h3>
 
-
Bandung Institute of Technology (ITB) iGEM 2013 team conducted interviews with 5 random citizens in Indonesia. The interviewees came from different background. The interviews reveal that all of the interviewees did not know what synthetic biology meant. (R.N, 2013). The term synthetic biology did appear in newspapers and blogs, but no formal studies have been conducted to measure the perception of synthetic biology in Indonesia. Considering that not many people are fully understand with the term biotechnology, it seems like the concept synthetic biology, a relatively new field, is even less prevalent.<br><br>
 
-
<center><img src="https://static.igem.org/mediawiki/igem.org/6/6a/Indonesia_perception_of_synthetic_biology_1.png"></center><br>
 
-
 
-
</div>
 
-
</div>
 
<div class="row">
<div class="row">
<div class="nine columns"><p id="5"></p>
<div class="nine columns"><p id="5"></p>
-
<h3>Research, People & Organizations</h3>
+
<h3>Pictures</h3>
-
<h5>Research</h5>
+
<center><img src="https://static.igem.org/mediawiki/2013/c/c1/Yu1.jpg" style="width:30%;margin:10px;"><img src="https://static.igem.org/mediawiki/2013/2/29/Yu2.jpg" style="width:30%;margin:10px;"><img src="https://static.igem.org/mediawiki/2013/9/9a/Yu3.jpg" style="width:30%;margin:10px;"></center><br>
-
Scientists in Indonesia are actively conducting researches related to biology and biotechnology. For example, Indonesian Institute of Sciences Biotechnology Research Center (LIPI) has been conducting numerous researches related to biotechnology. It is probably these kinds of research institutes that will adopt synthetic biology techniques once it becomes more prevalent in Indonesia.
+
</div>
-
<br><br>
+
</div>
-
The following table summarizes some of the researches of LIPI<br><br>
+
-
<center><img src="https://static.igem.org/mediawiki/igem.org/b/b3/Indonesia_research_people_and_organization_1.png"></center><br><br>
+
-
<h5>People</h5>
+
-
<center><img src=""></center><br><br>
+
-
<h5>Organization</h5>
+
-
There are several science organizations that could be found online. Some of them are in the field of biotechnology. None of them are explicitly related to synthetic biology.
+
-
<p id="msk1">1. Indonesian Institute of Science (LIPI)<br>
+
-
2. Indonesian Academy of Sciences (AIPI)<br>
+
-
3. PT. Biotek Sarana Industri: A private industry that works in the field of biotechnology, chemical trading, agro</p><p id="msk3">industry and pharmaceutical for pest control at commodity warehouse and farms.</p>
+
-
<p id="msk1">4. PT. Jirona Agritama: A subsidiary of Biotech Group, which is engaged in trade in agricultural products</p><p id="msk3">and plantations like oil palm, rubber, andcocoa, the main herbicide and insecticide products.</p>
+
-
<p id="msk1">5. KALBE: A public pharmaceutical company, which focused on prescription pharmaceuticals, consumer health <p id="msk3">products, nutritionals, and distribution and logistics. Kalbe established two institutes:</p><br></p>
+
-
<p id="msk2">a. Stem Cell and Cancer Institute (SCI): SCI is a center for stem cell and cancer research, prepared to be the</p><p id="msk4">basis for future therapy development to replace conventional drugs and therapy.</p>
+
-
<p id="msk2">b. Innogene Kalbiotech: A subsidiary of Kalbe established as a basis to develop competence in biotechnology-</p><p id="msk4">based products. Innogene is actively involved in the acquisition, development and commercialization of products, one of the most prominent being TheraCIM, a monoclonal antibody for targeted cancer therapy.<br></p>
+
-
<h5>Education</h5>
+
-
There thousands of universities in Indonesia, but only some of them teach synthetic biology or biotechnology. Some universities don’t have biology course. Biotechnology and synthetic biology are taught mainly in big universities such as University of Indonesia and Gajah Mada University.<br><br>
+
-
<center><img src="https://static.igem.org/mediawiki/igem.org/b/ba/Indonesia_research_people_and_organization_4.png"></center><br>
+
-
</div>
+
-
</div>
+
<div class="row">
<div class="row">
<div class="nine columns"><p id="6"></p>
<div class="nine columns"><p id="6"></p>
-
<h3>References</h3>
+
<h3>Download Links</h3>
-
<br>
+
<i>Right-click and click "Save link as..." on the link to items that you want to download.</i>
-
<p><strong>iGEM Competition</strong> <br>
+
<br><br>
-
  <em>Daftar lengkap perguruan tinggi negeri dan swasta di indonesia</em>. (n.d.). Retrieved from jamarisonline.blogspot.hk/2011/06/daftar-lengkap-perguruan-tinggi-negeri.html <br>
+
<a href="https://static.igem.org/mediawiki/2013/c/c8/Interview_Appendix_-_Prof._Yu.pdf">Prof. Yu's Interview Script (PDF)</a>
-
  <em>Figure:</em><br>
+
-
  [Image]. Retrieved August 21, 2013, from: tatiuc.edu.my/icet2013/LOGO/ipb.gif <br>
+
-
  [Image]. 2013. Retrieved August 21, 2013, from: banpt.blogspot.hk/2013/02/akreditasi-ban-pt-itb-tahun-2013.html <br>
+
-
  [Image]. Retrieved August 21, 2013, from: mhs.blog.ui.ac.id/roboboatui/category/uncategorized/<br>
+
-
  <br>
+
-
  <strong>Funding of Biotechnology</strong> <br>
+
-
  <em>Riset bioteknologi: Terkendala minimnya anggaran</em>. (2012, July 16). Retrieved from www.ipotnews.com/index.php?jdl=RISET_BIOTEKNOLOGI__terkendala_minimnya_anggaran&amp;level2=newsandopinion&amp;level3=&amp;level4=marketoverview<br>&amp;id=1465932 <em>Dana 2012</em>. (2013, July 10). Retrieved from www.biotek.lipi.go.id/index.php/profile/dana <br>
+
-
  <em>Figure:</em><br>
+
-
  [Image]. <strong>Retrieved</strong> August 21, 2013, <strong>from</strong>: www.koki.lipi.go.id/ <br>
+
-
  [Image]. <strong>Retrieved</strong> August 21, 2013, <strong>www.nyananews.com/2013/05/30/bppt-minta-e-voting-dimulai-jembrana/<br>
+
-
  <br>
+
-
  </strong><strong>Perception of Synthetic Biology</strong> <br>
+
-
R.N, R. (2013).&nbsp;<em>Imajinasi masyarakat indonesia tentang sel</em>[Web]. Retrieved from: synbio.itb.ac.id/ <br>
+
-
<br>
+
-
<strong>Research, People, Organization</strong> <br>
+
-
  Santoso, A., Kitagawa, N., Wardiana, A., Kusumawati, A., Puji Septisetyani, E., Kawaichi, M., Rubiyana, Y., &amp; Hadiwisnuwardhani, P. (2012). Producksi Protein Farmasetik Recombinant Human Erythropoietin (rhepo) dengan Modifikasi Pola Glikosilasi. Retrieved from insentif.ristek.go.id/PROSIDING2012/file-KO-Word_32.pdf <br>
+
-
  Zaenal Mustopa, A., Susilaningsih, D., Sukmarini, L., Ridwan, M., Delicia, &amp; Hasim (2012). Pengembangan polisakarida dari mikroalga btm 11 sebagai inhibitor rna helikase virus hepatitis c. Retrieved from insentif.ristek.go.id/PROSIDING2012/file-KO-Word_26.pdf <br>
+
-
  Zaenal Mustopa, A., Tarman, K., &amp; Safithri, M. (2012). Pengembangan protein antikanker dari kapang endofit indigenous laut indonesia xylaria psidii kt30. Retrieved from insentif.ristek.go.id/PROSIDING2012/file-KO-Word_40.pdf <br>
+
-
  <em>Figure:</em><br>
+
-
  [Image]. Retrieved August 21, 2013, from: www.koki.lipi.go.id/ <br>
+
-
  [Image]. Retrieved August 21, 2013, from: <a href="http://www.biotek-group.com/sarana_industri/index.html">www.biotek-group.com/sarana_industri/index.html</a> <br>
+
-
  [Image]. Retrieved August 21, 2013, from: <a href="http://logos.wikia.com/wiki/Kalbe">logos.wikia.com/wiki/Kalbe</a> <br>
+
-
  [Image]. Retrieved August 21, 2013, from: <a href="http://www.innogene-kalbiotech.com/">www.innogene-kalbiotech.com/</a> <br>
+
-
  [Image]. Retrieved August 21, 2013, from:  <a href="http://www.ugm.ac.id/new/en/about-us/meaning-symbol.xhtml">www.ugm.ac.id/new/en/about-us/meaning-symbol.xhtml</a> <br>
+
-
  [Image]. Retrieved August 21, 2013, from: <a href="http://www.ubaya.ac.id/">www.ubaya.ac.id/</a> <br>
+
-
[Image]. Retrieved August 21, 2013, from:  www.unud.ac.id/eng/official-shield-and-motto/logo </p>
+
-
</div>
+
-
</div>
+
</div>
</div>
</div>
</div>
 +
</div>
 +
</div>
</body>
</body>
</html>
</html>

Latest revision as of 12:56, 28 October 2013

Prof. Albert Yu

Overview

Professor Albert Yu is the chairman of the Hong Kong Biotechnology Organization (HKBIO), and also a professor of the Department of Neurobiology of Peking University, China. As an entrepreneur and a scientist, Prof. Yu gave us realistic insights to our project. Meeting Prof. Yu helped us to evaluate our project beyond the laboratory environment and to think about its possible future application as a biotechnology product. Towards the end of the interview, we also talked about the bioethics and biosafety issues regarding synthetic biology.

Main Discussion

Prof. Yu mentioned that our project is a small step and that we have a long way to go to apply our project as a commercial biotechnology product. He told us that because we are trying to insert genes into a human body, we need to be very careful with concluding how our project could be realistically applied in the future. Inserting genes into a human body can create novel metabolism properties that could lead to side effects. Also, because the general public considers obesity less harmful, people might be reluctant to sign up for invasive treatment if they believe a less invasive means such as exercising can solve the problem. He also encouraged us to look into other plant genes that could be used to cure fatal diseases.

We also discussed about issues on biosafety and bioethics. Prof. Yu said that we need to be responsible scientists and utilize research to improve human life. He also mentioned that to produce a bioproduct, it is very important to consider the ethical issues of the project from the very start.

Conclusion

The interview with Professor Albert Yu helped us to realize the social environment our project would encounter, and the barriers that come with it. The interview also showed that more in-depth consideration of our project’s future application is necessary if we want to see it utilized as a safe bioproduct.

Pictures


Download Links

Right-click and click "Save link as..." on the link to items that you want to download.

Prof. Yu's Interview Script (PDF)

Retrieved from "http://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview/yu"